@ram1984
In case of investing in any company, the younger you catch it, higher the chances of making bigger returns. This is the holy grail of fundamental investors. They latch on to subtle changes seen in companies and can make a case for big returns. I have seen Ayush pointing out about small parts of narratives in avanti feeds annual reports many years back because of which he got the conviction to buy avanti when no one was looking at it.
But one cannot get it all right all the time. Sometimes you miss out on a story when it is supposed to be caught on to. But its always to join the party better late then never. (provided there is enough valuation comfort).
For those interested in Laurus history and journey, I Found this link on whatsapp. I can see a couple of lines I wrote on VP (in reply to someone) in the article. 
If we are invested in a company, we should have a rough estimate of what kind of earnings we are expecting in the near term, say 1-2 years atleast. Beyond that, one can have a guess at the general trajectory of earnings but even approximate estimates are difficult bcos things can change a lot in this ever changing world.
So for me, I try to listen to concall, go through AR, presentations and try to make a guess how latest quarter results have been and whether that performance can be repeated or bettered. In both alembic and laurus, I get a sense that the q1 numbers are repeatable or can be bettered.
In case of laurus, Dr Chhava has been confident about business prospects and order book and there are strong tailwinds for the business, besides new emerging engines for growth.
In alembic, the domestic portfolio which was not matching up to export portfolio should start firing sooner rather than later. Only a 5% decline in q1 in domestic portfolio growth , especially in a quarter where footfalls in hospitals were largely curtailed by lockdown, was very encouraging data point for me. Besides, this, the sartans traction continues (and alembic has the advantage of being fully integrated in sartans right from api to formulations), and other exports base business also remains strong. Besides this, even post the run up from all time high of 790 to 1100 and now around 920-930, valuations look attractive. Yet another optionality lies in rhizen where alembic has 50% stake. Rhizen is entitled to milestone payments on completion of certain milestones ( filing and approval being one of the milestone and this will trigger milestone payment in near future), royalty on sales and probable manufacturing contracts. Besides it continues to get lucky breaks, the lastest one being famotidine windfall. So for me, it becomes a very attractive proposition.
About debt being present in alembic and laurus and alkem and not much in divis, we have to figure out why debt was taken . If it was taken to invest in same line of business and is within reasonable limits, it is a non issue. Digging too much into these things is like ābaal ki khaal nikalna.ā 
So in both cases adding at current levels also could be easy but I donāt have too much space to add these two because of portfolio allocation constraints.